AXDX Accelerate Diagnostics Inc

Price (delayed)

$8.11

Market cap

$495.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$605.23M

Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC ...

Highlights
The revenue has grown by 15% year-on-year
Accelerate Diagnostics's EPS has increased by 7% YoY
The company's net income fell by 3.7% QoQ but it rose by 3.3% YoY
AXDX's equity has shrunk by 189% YoY and by 6% QoQ
The quick ratio fell by 35% YoY and by 7% QoQ

Key stats

What are the main financial stats of AXDX
Market
Shares outstanding
61.04M
Market cap
$495.07M
Enterprise value
$605.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
41.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.37
Earnings
Revenue
$11.34M
EBIT
-$65.24M
EBITDA
-$62.34M
Free cash flow
-$47.1M
Per share
EPS
-$1.42
Free cash flow per share
-$0.8
Book value per share
-$1.12
Revenue per share
$0.19
TBVPS
$1.58
Balance sheet
Total assets
$92.67M
Total liabilities
$159.03M
Debt
$152.89M
Equity
-$66.36M
Working capital
$74.45M
Liquidity
Debt to equity
-2.3
Current ratio
11.11
Quick ratio
9.32
Net debt/EBITDA
-1.77
Margins
EBITDA margin
-549.8%
Gross margin
37.9%
Net margin
-715.5%
Operating margin
-582%
Efficiency
Return on assets
-80.1%
Return on equity
N/A
Return on invested capital
-32%
Return on capital employed
-76.5%
Return on sales
-575.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXDX stock price

How has the Accelerate Diagnostics stock price performed over time
Intraday
-5.7%
1 week
-7.31%
1 month
14.23%
1 year
-36.24%
YTD
6.99%
QTD
-2.52%

Financial performance

How have Accelerate Diagnostics's revenue and profit performed over time
Revenue
$11.34M
Gross profit
$4.3M
Operating income
-$66M
Net income
-$81.14M
Gross margin
37.9%
Net margin
-715.5%
Accelerate Diagnostics's operating margin has increased by 20% YoY but it has decreased by 2% from the previous quarter
The gross margin fell by 19% YoY and by 5% QoQ
AXDX's net margin is up by 16% YoY but it is down by 2.1% QoQ
The revenue has grown by 15% year-on-year

Growth

What is Accelerate Diagnostics's growth rate over time

Valuation

What is Accelerate Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
41.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
53.37
Accelerate Diagnostics's EPS has increased by 7% YoY
AXDX's equity has shrunk by 189% YoY and by 6% QoQ
AXDX's price to sales (P/S) is 96% less than its 5-year quarterly average of 934.8 and 22% less than its last 4 quarters average of 53.9
The revenue has grown by 15% year-on-year

Efficiency

How efficient is Accelerate Diagnostics business performance
Accelerate Diagnostics's ROA has decreased by 34% YoY and by 11% from the previous quarter
Accelerate Diagnostics's ROS has increased by 18% YoY but it has decreased by 2.5% from the previous quarter
Accelerate Diagnostics's return on invested capital has increased by 11% YoY but it has decreased by 6% QoQ

Dividends

What is AXDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXDX.

Financial health

How did Accelerate Diagnostics financials performed over time
The company's total assets is 42% lower than its total liabilities
The quick ratio fell by 35% YoY and by 7% QoQ
The company's current ratio fell by 31% YoY and by 6% QoQ
AXDX's equity has shrunk by 189% YoY and by 6% QoQ
Accelerate Diagnostics's debt to equity has soared by 61% YoY and by 3.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.